Abbisko Therapeutics - 上海和誉生物医药科技有限公司-LIST

Press Releases

Addressing patient needs through scientific driven innovation

We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and worldwide.

Press Releases

Abbisko Therapeutics Presents Updated Clinical Progress on Irpagratinib and Pimicotinib at European Society for Medical Oncology (ESMO) 2024

Sep 18, 2024

Abbisko Therapeutics will present the latest clinical results of Irpagratinib at the 2024 ESMO Congress

Aug 01, 2024

Abbisko Therapeutics announced a positive profit alert for the first half of 2024

Jul 11, 2024

2024 ESMO-GI | Abbisko Therapeutics presents new phase II clinical data of irpagratinib in combination with atezolizumab for advanced hepatocellular carcinoma

Jun 28, 2024

Abbisko and Allist Pharmaceuticals Jointly Announce the Initiation of a Phase 2 Clinical Study Evaluating oral PD-L1 small molecule ABSK043 in Combination with Furmonertinib Mesylate Tablets for the Treatment of Advanced Non-Small Cell Lung Cancer

May 09, 2024

Abbisko Therapeutics Completes Dosing of the First Patient in the Phase II Clinical Trial for ABSK011 in Combination with an Anti-PD-L1 Antibody

Feb 08, 2022

View all

we discover and develop first-in-class and best-in-class therapies

to address critical unmet needs for cancer patients in China and globally

Media

PharmaBoardroom interviews Dr. Xu Yaochang, the founder and CEO of Abbisko

Jul 17, 2024

Bioworld: Abbisko out-licenses pimicotinib to Merck KGaA in $605M deal

Dec 12, 2023

Endpoints: Abbisko signs $70M upfront deal with Merck KGaA for PhIII cancer drug

Dec 05, 2023

FierceBiotech:Merck KGaA buys into Abbisko’s late-stage joint tumor med for $70M upfront

Dec 05, 2023

View all